刚摘帽，又戴帽：ST百灵 “帽子戏法”背后的11亿造假！

Core Viewpoint - Guizhou BaiLing has been repeatedly penalized and labeled as ST (special treatment) due to ongoing financial misconduct, leading to significant management and operational instability [2][3][7]. Financial Misconduct - The company has been involved in a cycle of financial manipulation, with a total of 1.114 billion yuan adjusted over four years, showcasing a pattern of inflating and deflating profits [5][6]. - The China Securities Regulatory Commission (CSRC) issued a record fine of 25.6 million yuan, indicating severe regulatory scrutiny and the ineffectiveness of the company's internal control reforms [7]. Management Issues - The company's actual controller, Jiang Wei, has been banned from the market for ten years, which poses a significant threat to the company's strategic stability [2][7]. - Jiang Wei is embroiled in a legal dispute with Huachuang Securities, which is seeking repayment of 1.7 billion yuan, further complicating the company's financial situation [10][11]. Financial Performance - Guizhou BaiLing's revenue for 2024 was 3.825 billion yuan, a decline of 10.26% year-on-year, with a net loss of 82.44 million yuan, primarily relying on government subsidies to mitigate losses [13]. - In the first three quarters of 2025, revenue continued to decline by 24.28%, with a net profit of only 21.21 million yuan, indicating ongoing financial challenges [13]. Research and Development - The company's R&D expenditure has been significantly lower than industry peers, with R&D expenses as a percentage of revenue at 0.82%, 1.95%, and 1.59% from 2022 to 2024, compared to an average of 4.17% to 4.86% among 69 listed traditional Chinese medicine companies [14]. - The core R&D project, "Tang Ning Tong Luo," has not yet completed its Phase III clinical trials, raising concerns about its future revenue potential [14]. Sales and Market Dependency - Guizhou BaiLing's sales expenses are alarmingly high, with a sales expense ratio of 48.46% in 2024, nearly four times that of Yunnan Baiyao [14]. - The company relies heavily on a concentrated customer and supplier base, with the top five customers accounting for nearly 40% of revenue and the top five suppliers for over 45% of purchases, which could jeopardize its operational stability [16].